Objective: Genome-wide association (GWAS) methods have identified genes contributing to Parkinson's disease (PD); we sought to identify additional genes associated with PD susceptibility. Methods: A 2-stage design was used. First, individual level genotypic data from 5 recent PD GWAS (Discovery Sample: 4,238 PD cases and 4,239 controls) were combined. Following imputation, a logistic regression model was employed in each dataset to test for association with PD susceptibility and results from each dataset were metaanalyzed. Second, 768 single-nucleotide polymorphisms (SNPs) were genotyped in an independent Replication Sample (3,738 cases and 2,111 controls). Results: Genome-wide significance was reached for SNPs in SNCA (rs356165; G: odds ratio [OR] ¼ 1.37; p ¼ 9.3 Â 10 À21 ), MAPT (rs242559; C: OR ¼ 0.78; p ¼ 1.5 Â 10 À10 ), GAK/DGKQ (rs11248051; T: OR ¼ 1.35; p ¼ 8.2 Â 10 À9 / rs11248060; T: OR ¼ 1.35; p ¼ 2.0 Â 10 À9 ), and the human leukocyte antigen (HLA) region (rs3129882; A: OR ¼ 0.83; p ¼ 1.2 Â 10 À8 ), which were previously reported. The Replication Sample confirmed the associations with SNCA, MAPT, and the HLA region and also with GBA (E326K; OR ¼ 1.71; p ¼ 5 Â 10 À8 Combined Sample) (N370; OR ¼ 3.08; p ¼ 7 Â 10 À5 Replication sample). A novel PD susceptibility locus, RIT2, on chromosome 18 (rs12456492; p ¼ 5 Â 10 À5 Discovery Sample; p ¼ 1.52 Â 10 À7 Replication sample; p ¼ 2 Â 10 À10 Combined Sample) was replicated. Conditional analyses within each of the replicated regions identified distinct SNP associations within GBA and SNCA, suggesting that there may be multiple risk alleles within these genes. Interpretation: We identified a novel PD susceptibility locus, RIT2, replicated several previously identified loci, and identified more than 1 risk allele within SNCA and GBA.
P arkinson's disease (PD) is the second most common adult-onset neurodegenerative disorder worldwide. 1 Five genes have been identified with mutations that result in Mendelian forms of PD; however, mutations have been found in fewer than 5% of individuals with PD, suggesting additional genes contribute to disease risk. 2 Many candidate gene studies and several genome-wide association studies (GWASs) have been performed to identify risk factors for PD, with growing evidence for the role of SNCA, MAPT, GBA, GAK/DGKQ, and the human leukocyte antigen (HLA) region in disease susceptibility. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Two recent studies found evidence for association with additional loci, including ACMSD, STK39, MCCC1/LAMP3, SYT11, CCDC62/HIP1R, STX1B, FGF20, STBD1, GPNMB, and PARK16. 11, 13 However, there is evidence that there are additional loci yet to be identified.
Materials and Methods

Discovery Sample
To identify additional genes associated with PD, we combined publicly available genotype level GWAS data obtained from dbGaP 4, 6 along with 2 new datasets that are not yet publicly available and were obtained directly from the investigator who performed the GWAS. 5, 7, 8 All datasets employed standard UK Brain Bank criteria 14 for the diagnosis of PD, with a modification to allow the inclusion of cases that had a family history of PD. This modification was made because it is believed that familial PD cases may have a stronger genetic contribution than sporadic PD, making them potentially more informative for genetic studies. PD cases with a reported age of onset below 18 years of age were removed from the dataset (n ¼ 17) . When data were available, any PD cases known to harbor a causative mutation, either 2 parkin mutations or a single LRRK2 mutation, were excluded from further analysis (n ¼ 57).
An Illumina genotyping array (Illumina, San Diego, CA) was used by all studies. Individual level genotypic data was available and reviewed across studies to identify sample duplicates (see Supplemental Methods). Prior to performing imputation, each study was subjected to rigorous quality review and data cleaning (see Supplemental Methods for more details) and principal component analysis was used to control for population stratification. Imputation was then performed for all autosomes using MACH 1.0 (Li and colleagues 15 ). The 2.5 million HapMap2 single-nucleotide polymorphisms (SNPs) were analyzed using ProbABEL (http://www.genabel.org/packages) and a logistic regression model, that included sex and age, when appropriate (see Supplemental Methods). Meta-analysis was performed with METAL (http://www.sph.umich.edu/csg/abecasis/ Metal) using an inverse-variance weighting scheme. This allowed an overall effect size to be estimated. Genomic control was employed so that results were down-weighted if the study's lambda exceeded 1.00. The Discovery Sample was large enough to have 80% power to detect relative risks as small as 1.14 to 
SNP Selection for Replication Genotyping
A custom Illumina genotyping array was designed with 768 SNPs that included the following:
• Known causative mutations: SNPs that genotyped 2 common LRRK2 mutations in European populations (G2019S and R1441H);
• Known risk factors: GBA (N370S, L444P, E326K, T369M); • Previous GWAS associations: PARK16, 6, 12 LRRK2, 6, 12 SNCA, [5] [6] [7] [8] 12 MAPT, [5] [6] [7] [8] 5, 8 and the HLA region 8 ;
• Sex confirmation: Three SNPs on the Y chromosome and 6
SNPs on the X chromosome in addition to the sex-specific probes included in the GoldenGate custom oligonucleotide pool;
• Top priority association results from the meta-analysis: SNPs were selected based on increasing p. A SNP was removed from consideration if it was in linkage disequilibrium (LD) (r 2 > 0.80) with a SNP having a smaller p or had an Illumina design score less than 0.40 (if p < 1 Â 10 À5 ) or 0.60 (if p ! 1 Â 10 À5 ). This approach identified 619 SNPs (all p < 3.2 Â 10 À4 ). In addition, 28 additional SNPs were selected in the highest priority regions (p < 1 Â 10 À5 ), in case 1 of the SNPs in these regions failed quality assessment after being genotyped on the replication array (eg, call rate < 0.98, divergence from Hardy-Weinberg equilibrium (HWE) in controls p < 0.0001); and
• Ancestry informative markers (AIMs): SNPs were selected based on fixation indices (F ST ) between the Ashkenazi and British population clusters as defined using annotated results from Eigenstrat (see Supplemental Fig. 1 ). Markers were then ranked based on how well they differentiated between the 2 subpopulations, and 100 were selected in a manner similar to the 619 replication SNPs. A SNP was excluded from further consideration if it was in LD (r 2 > 0.05) with any marker with a larger F ST , or if it had an Illumina design score less than 0.80. Samples were genotyped by the Genetic Resource Core Facility SNP Center at Johns Hopkins University using Illumina GoldenGate chemistry 16 and a custom panel of 768 SNPs (GS0012520-OPA) (see Supplemental Methods).
Replication Sample
The independent Replication Sample included 3,738 PD cases and 2,111 controls. Samples were obtained either from an established repository (Coriell Repositories or National Cell Repository for Alzheimer Disease) that assured the samples had appropriate consent for sample and data sharing or directly from the investigator who had collected the sample, and whose study was approved by the appropriate Human Subject Committee at their institution. All samples included in the Replication Sample were reported as white, non-Hispanic. All cases underwent a neurological evaluation that employed PD diagnostic criteria based broadly on the UK PD Society Brain Bank Criteria, 17 although modified to allow a positive family history of PD. Three cases reported an age of onset 18 years and were excluded from further study. When information was available, cases were excluded if they were known to harbor a causative mutation (either 2 parkin mutations or a single LRRK2 mutation). Controls were selected, when possible, from the same study that also provided cases. Based on selfreport, the control subjects did not have a personal history of PD.
The first level of data review focused on genotyping quality (SNP completeness). The second level focused on which samples and which SNPs would be included in analyses. The multidimensional scaling (MDS) algorithm implemented in PLINK (http://pngu.mgh.harvard.edu/$purcell/plink) was performed using the 100 AIMs and all other independent SNPs (SNPs with r 2 > 0.30 were not included) to confirm that all samples were indeed white and non-Hispanic. Samples with an LRRK2 mutation were removed from further analysis, as were any that were cryptically identical to an individual in the Discovery sample. More details are available in the Supplemental Methods.
We utilized the same logistic regression model used in the initial meta-analysis to analyze the Replication Sample. The initial analysis included the 619 SNPs designed to replicate our top priority association results. Unlike the Discovery Sample, in which each study included both cases and controls, the Replication Sample included some studies providing both cases and controls, while others provided only cases or only controls. Therefore, we could not analyze each sample separately as we had in the Discovery Sample analyses. Rather, the entire Replication Sample was analyzed together. The mean age at exam of the controls was later than the mean age at onset of the cases; therefore, we did not include age in the logistic regression model. There were statistically significant sex differences between the cases and controls. Therefore, the final analytic model included both sex as well as 1 principal component to adjust for the population stratification due to the disproportionate Ashkenazi Jewish ancestry of the cases. All analyses were performed using PLINK. Odds ratios (ORs) and p values were computed to assess the strength of the association. After excluding AIMs and considering LD between SNPs as implemented in SimpleM, 18 there were 530 effectively independent tests, requiring a corrected threshold of p < 9 Â 10 À5 for an association to be considered replicated in the Replication Sample
Joint Analyses
We performed a meta-analysis to combine the results of the independent Discovery and Replication Samples only for the SNPs successfully genotyped in the Replication Sample. We used the same analytic approach as in the Discovery Sample. An association was considered statistically significant if the p value in the joint analyses exceeded genome-wide significance (p < 5 Â 10 À8 ).
To test the hypothesis that there might be more than 1 risk variant in a particular gene or gene region contributing to the association, we performed conditional analyses. For each statistically significant gene/region, we identified the SNP with the most extreme p value in the combined Discovery and Replication samples. We then modified the logistic regression model to include not only sex and the principal component covariate, but also the genotype at the most significant SNP. We then reviewed the p value for the other SNPs in the gene/region to determine if any other SNPs remained statistically significant (gene-wide empirical p < 0.05 using permutation testing) after adjusting for the effect of the most significant SNP. In this way, we could identify genes/regions in which more than 1 SNP provided distinct evidence of association with PD susceptibility.
Ingenuity Pathway Analysis (IPA) software was used to search for biological relationships among the genes meeting genome-wide significance. A gene list (DGKQ, GAK, the HLA region, MAPT, SNCA, and RIT2) was entered into a ''My Pathway'' analysis in IPA. Restricting species to human and allowing for findings among chemicals, the Path Explorer tool under the Build tab was used to search among the Ingenuity knowledge base and external databases to identify the shortest pathways among the genes with either no or 1 intervening molecule. Links between genes represent protein-protein interactions or indicate that 1 gene influences phosphorylation of the connected gene. 
The individual level genotypes for PROGENI/GenePD, the NIA Phase I and II, and NGRC are all available through dbGaP. a Number of SNPs in filtered dataset prior to imputation. This is the number of unambiguous (ie, no A/T or C/G pairings) SNPs passing all quality assessment. b A plus sign (þ) for age indicates an association between PD risk and older age. Those studies in which the age at onset of the cases was significantly older than the age at exam of the controls are in bold; age was included as a covariate in these studies only. c A plus sign (þ) for male indicates an association between higher PD risk and male sex; sex was included as a covariate for all studies.
Meta-analysis was performed combining the results from each dataset to identify SNPs associated with PD susceptibility ( Fig. 1 , Table 2 ). Genome-wide significance (p < 5 Â 10 À8 ) was reached for SNPs in SNCA (rs356165;
, and the HLA region (rs3129882; OR ¼ 1.21; p ¼ 1.2 Â 10 À8 ), which have been previously established in PD susceptibility. No other regions exceeded genome-wide thresholds of significance; however, 28 SNPs had association results with p < 10 À5 (see Supplemental Table 1 for complete results). Distinct clusters could be identified based on ancestry (see Supplemental Results). However, none of the genome-wide significant findings could be explained by ancestry. These were tested in 3 ways: (1) adjusting for principal components; (2) adjusting for cluster membership; and (3) stratifying by cluster membership.
Replication Sample
The Replication Sample is summarized in Table 3 . Genotypes were successfully generated for 705 of 768 attempted SNPs (92%). The only notable SNP loss was the GBA L444P SNP, which failed to genotype presumably because of the homology with the neighboring pseudogene.
Data was released for 5,794 study samples (>99% of attempted samples) and 123 blinded duplicate study samples. Detailed review of samples was performed to remove samples that were unexpected duplicates, poorly performing, or did not cluster as Caucasian, non-Hispanic (see Supplemental Results). All samples identified with a causative LRRK2 mutation were eliminated from further analysis (n ¼ 61 cases, 1 control).
Analysis of the Replication Sample confirmed the previously identified associations with SNCA, MAPT, the HLA region, and GBA ( Fig. 2 ; complete results in Supplemental Table 2 ). Only the GAK/DGKQ region was not statistically significant (p ¼ 0.01). We replicated a novel locus on chromosome 18 within the RIT2 gene that is in LD with markers in nearby SYT4 (rs12456492; p ¼ 2 Â 10 À7 ; Fig. 3 ). Given the regional LD, determining if the underlying functional variation affects 1 gene product vs the other can be difficult to discern, as is the case with the GAK/DGKQ locus.
Joint Analysis
With the power of the joint analysis of the Discovery and Replication Samples, GBA now reached genomewide significance. Many additional SNPs in GAK/ DGKQ, SNCA, the HLA region, and MAPT reached significance. Our newly identified locus, RIT2, also met genome-wide criteria in this joint analysis (OR ¼ 1.19; p ¼ 2 Â 10 À10 ) ( Table 4) .
To further explore the association results in each gene, we performed conditional analyses in the combined samples. We detected 2 distinct effects within the GBA locus (see Table 4 ). The SNPs with the most extreme p values in the Combined Sample were rs12726330 and the E326K variant, which both reached genome-wide significance (p ¼ 5 Â 10 À8 ). These 2 SNPs are in high LD with each other, so when 1 genotype is included in a logistic regression model, the other becomes nonsignificant. When E326K is included in the logistic model, another SNP remained statistically significant (N370S; p < 7 Â 10 À5 ). All results included the principal component that accounts for Ashkenazi ancestry, which controls for the increased incidence of GBA mutations in the Ashkenazi population. Moreover, when individuals within the Ashkenazi cluster were excluded from the Discovery Sample and the Replication Sample, the association to rs12726330 and to E326K remained at genome-wide significance (Discovery Sample: 3,792 cases, 3,842 controls, p ¼ 2 Â 10 À5 ; Replication Sample: 3,025 cases, 1,931 controls, p ¼ 0.0005; Combined Sample: p < 5 Â 10 À8 ). We detected 2 distinct associations at the SNCA locus (see Table 4 ); 1 association that is tagged by rs356220 and the other tagged by rs356198. The second association, tagged by rs356198, still exceeded genomewide significance when conditioning on rs356220 (p ¼ 5 Â 10 À9 ). Our results are corroborated by other studies which identified independent associations within SNCA. 9, 10, 12 See Supplementary Methods and Supplementary Table 6 for more information.
We assessed the biological relationships among the genome-wide significant genes identified in our study (Fig. 4) . Paths between genes represent protein-protein interactions or phosphorylation. This network suggests that GAK and RIT2 may be part of the same disease pathway as MAPT and SNCA, while DGKQ and the HLA region may influence risk of PD via another mechanism.
Discussion
We performed a large meta-analysis including 2 studies not included in any reported meta-analysis. The Discovery and Replication samples were well characterized and established criteria were utilized for the diagnosis of PD. Both sporadic and familial PD cases were included. Cases with a known causative mutation were excluded (ie, LRRK2 mutation; 2 parkin mutations). Using a rigorous 2-stage design, we identified a novel locus, RIT2, associated with PD susceptibility. In addition, we also replicated loci previously associated with PD, including GAK, SNCA, the HLA region, and MAPT. Pathway analyses suggest that GAK and RIT2 may be part of the same disease pathway as MAPT and SNCA, while DGKQ and the HLA region may influence risk via another mechanism.
We detected genome-wide significant evidence of association to RIT2, a gene proposed in previous studies but which did not meet stringent statistical criteria as a risk factor for PD. The protein encoded by human RIT2 binds to the product of human calmodulin 1 (phosphorylase kinase, delta) CALM1. 19 Of note, CALM1 binds to human SNCA and MAPT. 20, 21 Comparison of gene expression in brain tissue from neuropathologically confirmed PD cases and controls demonstrates reduced expression of RIT2 in the remaining portion of the substantia nigra. 22 Results from our GWAS, pathway analysis, and expression studies provide supporting biological evidence that RIT2 acts as a PD gene and suggest a starting point for functional analysis.
We also explored the role of GBA variants in PD susceptibility. E326K is sometimes considered a benign polymorphism, since in the homozygous or compound heterozygous state it is not sufficient to cause Gaucher disease. However, results of this study and a previous study 23 indicate that E326K may be a susceptibility allele for PD. Most previous GWAS have not included all known GBA mutations in their analyses; for example, N370S is not included or tagged by GWAS arrays. However, we did ensure that this mutation was genotyped in our Replication Sample. Therefore, we were able to test in our Replication Sample for the association of GBA mutations and variants with PD susceptibility and then could utilize conditional analyses to determine that it was likely that there is more than 1 genetic factor in GBA influencing disease risk. Thus, our results suggest that additional analyses and potential functional studies are warranted to better delineate the role of GBA in PD susceptibility.
We also detected evidence of at least 2 distinct genetic effects within SNCA, a well-known PD susceptibility gene. While the SNP with the most extreme p value in the Discovery Sample (rs356165) failed to genotype in the Replication Sample, it is in complete LD (r 2 ¼ 1.0) with the most extreme p value in the Replication sample (rs356220). Moreover, they belong to the same LD block as the top SNP in other studies (rs356219; r 2 ¼ 0.96). 11 Two previous studies have reported high LD (D 0 ¼ 0.90) but low intermarker correlation (r 2 < 0.10) between the primary SNCA finding, rs356220, and the SNPs tagged (n) refers to the number of SNPs in the region where the p-value was less than 0.05 in the Combined Sample before conditioning on the index SNP and where the p-value was greater than 0.05 in the conditional analyses.
deleterious Rep1-263 allele. 24, 25 Rep1 is a microsatellite marker with 3 predominant alleles (259, 261, and 263) that has consistently been associated with PD risk and often with age at onset. The independent signal reported here, rs356198, is in high LD with the inversely associated Rep1-259 allele (in the PROGENI dataset: D 0 ¼ 0.92, r 2 ¼ 0.48). It is possible that the 2 independent SNPs are tagging a functional effect of Rep1 or that Rep1 is not functional, but merely tagging the same underlying causal variant(s) as the 2 SNPs. The SNP with the most extreme p value in the HLA region (rs3129882) was the same SNP identified in the NGRC sample that initially reported this association. 8 This is to be expected, because that study is included in our meta-analysis. This SNP was successfully genotyped in the Replication Sample, but was not statistically significant (p ¼ 0.92). Rather, a different SNP was statistically significant in the Replication Sample (rs2395163; p ¼ 1 Â 10 À5 ) and reached genome-wide significance in the Combined Sample (p ¼ 3 Â 10 À11 ). LD is high between the 2 SNPs (D 0 ¼ 0.92), but the correlation was low due to differing allele frequencies (MAF for rs3129882 ¼ 0.433; MAF for rs2395163 ¼ 0.197; r 2 ¼ 0.25). The allele frequency of rs2395163 is closer to that seen in the variant with the most extreme p value in the another recent meta-analysis of PD 11 (MAF for chr6:32588205 ¼ 0.15) and is in moderate to high LD with that SNP in the 1000 Genomes data (D 0 ¼ 1.00; r 2 ¼ 0.71). There is evidence that rs2395163 and chr6:32588205 tag the same LD block and that the association with these SNPs is independent of the original rs3129882 finding (see Supplementary Table 5 and Supplemental Methods).
Recently, another group reported results from a meta-analysis of several existing GWAS. 11, 13 Two of the Discovery Samples are in common in both studies and there is some overlap among our Replication samples, although the extent is difficult to quantify. There are several regions in common between studies. For example, both our study and theirs confirmed the association of GAK, SNCA, the HLA region, and MAPT. The 2 recent meta-analyses reported 10 new loci: ACMSD, STK39, MCCC1/LAMP3, SYT11, CCDC62/HIP1R, PARK16, NMD3, STBD1, GPNMB, FGF20, MMP16, and STX1B. Of note, SYT11 is within the same LD block on chromosome 1 as RIT1, whereas RIT2 is within the same LD block on chromosome 18 as SYT4. It remains to be seen which of these genes harbors the true susceptibility alleles and if they have an interaction within a common pathway leading to PD pathogenesis. Supplemental Table 3 summarizes the results in our study for the SNPs in the 10 new loci. We have nominal significance (p < 0.05) for all but 1 of these SNPs. Similar ORs in the same direction and for the same allele as presented in the original article was observed when analyses were limited to the 2 datasets not included in the original manuscript (Hussman Institute for Human Genomics [HIHG] and NeuroGenetics Research Consortium [NGRC]), and all but 3 SNPs remained nominally significant.
Comparing our results to those of recent GWASs, 1 other previously reported locus could be replicated by our analyses. BST1 has been seen in multiple datasets. 8, 9, 12 Although association to this locus did not meet our genome-wide criteria in either the Discovery or Combined Sample analyses, our results for SNPs in this gene did meet established criteria for replication of a previously reported association. The SNP rs4698412 had a p value of 0.002 in our Discovery Sample, 5 Â 10 À5 in our Replication Sample, and 3 Â 10 À7 in the Combined Sample.
In summary, we completed a meta-analysis of existing available PD GWAS datasets and identified a novel susceptibility locus, RIT2, and confirmed the association of several known genes. Using our Replication and Discovery Samples, conditional analyses confirmed that in 2 genes, there are multiple risk alleles that have distinct effects on disease risk. These results have important implications as studies are being designed to sequence these regions to identify all potentially functional diseaseassociated variants.
